Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call on Thursday, November 6, 2014
October 31 2014 - 6:00AM
Business Wire
Call Scheduled for 4 PM Eastern Standard
Time
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT)
(http://www.pvct.com), a development-stage oncology and dermatology
biopharmaceutical company, will host a quarterly conference call to
update the market in general and shareholders in particular about
developments at the Company. The call is scheduled for Thursday,
November 6, 2014 at 4:00 PM EST.
Those who wish to participate in the conference call may
telephone 877-407-4019 from the U.S. International callers may
telephone 201-689-8337, approximately 15 minutes before the call. A
webcast will also be available at: www.pvct.com.
A digital replay will be available by telephone approximately
two hours after the completion of the call until November 30, 2014,
and may be accessed by dialing 877-660-6853 from the U.S. or
201-612-7415 for international callers, and using the Conference
ID#13594370.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology
and dermatology therapies. PV-10, its novel investigational drug
for cancer, is designed for injection into solid tumors
(intralesional administration), thereby reducing potential for
systemic side effects. Its oncology focus is on melanoma, breast
cancer and cancers of the liver. The Company has received orphan
drug designations from the FDA for its melanoma and hepatocellular
carcinoma indications. PH-10, its topical investigational drug for
dermatology, is undergoing clinical testing for psoriasis and
atopic dermatitis. Provectus has recently completed Phase 2 trials
of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a
topical treatment for atopic dermatitis and psoriasis. Information
about these and the Company's other clinical trials can be found at
the NIH registry, www.clinicaltrials.gov. For additional
information about Provectus please visit the Company's website at
www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains
“forward-looking statements” as defined under U.S. federal
securities laws. These statements reflect management’s current
knowledge, assumptions, beliefs, estimates, and expectations and
express management’s current views of future performance, results,
and trends and may be identified by their use of terms such as
“anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,”
“may,” “plan,” “predict,” “project,” “will,” and other similar
terms. Forward-looking statements are subject to a number of risks
and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements.
Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking
statements include those discussed in our filings with the
Securities and Exchange Commission (including those described in
Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2013, and in our Quarterly Reports on Form 10-Q for
the quarters ended March 31, 2014 and June 30, 2014), and the
following:
• our determination, based on guidance from the FDA, whether
to proceed with or without a partner with a phase 3 trial of PV-10
to treat locally advanced cutaneous melanoma and the costs
associated with such a trial if it is necessary; • our
determination whether to license PV-10, our melanoma drug product
candidate, and other solid tumors such as liver cancer, if such
licensure is appropriate considering the timing and structure of
such a license, or to commercialize PV-10 on our own to treat
melanoma and other solid tumors such as liver cancer; • our ability
to license our dermatology drug product candidate, PH-10, on the
basis of our phase 2 atopic dermatitis and psoriasis results, which
are in the process of being further developed in conjunction with
mechanism of action studies; and • our ability to raise additional
capital if we determine to commercialize PV-10 and/or PH-10 on our
own, although our expectation is to be acquired by a prospective
pharmaceutical or biotech concern prior to commercialization.
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper,
866-594-5999 #30CFO, COOorPorter, LeVay & Rose, Inc.Marlon
Nurse, 212-564-4700DM, SVP – Investor RelationsorBill Gordon,
212-724-6312Media Relations
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024